Quince Therapeutics, Inc. - 8-K Filing
Quince Therapeutics regained compliance with Nasdaq listing requirements after reporting stockholders’ equity of $15.67 million in its March 31, 2026 quarterly report, satisfying the minimum market value requirement under Nasdaq Listing Rule 5450(b)(1)(A). The company had previously been notified on March 17, 2026 that it failed to maintain a $50 million minimum market value of listed securities. (Items: 8.01 Other Events)
Tickers: $QNCX